UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response

UroGen Shares ENVISION Trial Subgroup Analysis on Tumor Burden and UGN-102 Response UroGen Pharma Ltd. (Nasdaq: URGN) announced results from subgroup analyses of the pivotal ENVISION study, assessing the impact of tumor burden and focality on the response to UGN-102,…










